Cell Signaling Technology

Product Pathways - Metabolism

Phospho-SREBP-1c (Ser372) Antibody #9874

Applications Reactivity Sensitivity MW (kDa) Source
W H (M) (R) Transfected Only 150 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Phospho-SREBP-1c (Ser372) Antibody recognizes transfected levels of SREBP-1c protein only when phosphorylated at Ser372.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser372 of human SREBP-1c protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from serum-starved 293T cells treated with resveratrol (50 μM, 1 hr), transfected with a GST-tagged cDNA expression construct encoding either full-length human wild-type SREBP-1c (GST-hSREBP-1c) or full-length mutant SREBP-1c (GST-hSREBP-1c (S372A)), using Phospho-SREBP-1c (Ser372) Antibody (upper) or GST (91G1) Rabbit mAb #2625 (lower). Both expression vectors were generated in Dr. Mengwei Zang's laboratory at Boston University School of Medicine.

Background

Sterol regulatory element–binding proteins (SREBPs) are basic helix-loop-helix–leucine zipper transcription factors (1,2). Inactive precursor forms of SREBPs are bound to endoplasmic reticulum (ER) membranes (1,2). When cells are starved for cholesterol, SREBPs move from the ER to the Golgi apparatus with the help of SREBP cleavage–activating protein (SCAP) (1,2). In the Golgi apparatus, precursor SREBPs are then cleaved by two proteases, Site-1 protease (S1P) and Site-2 protease (S2P) (1,2). The released N-terminal domains enter the nucleus and bind to sterol response elements in the promoters of a variety of genes responsible for the synthesis of cholesterol (1,2). SREBPs also activate the expression of genes involved in the synthesis of fatty acids and lipids (1,2). Among the isoforms of SREBPs, SREBP-1c activates all lipogenic genes in the liver (3). SREBP-1c has been implicated to contribute to the development of hepatic steatosis in the rodent model of insulin resistance and obesity (3). Recent studies have shown that AMPK interacts with and directly phosphorylates SREBP-1c and SREBP-2 (4). Phosphorylation of SREBP-1c at Ser372 by AMPK, which is stimulated by polyphenols and metformin, inhibits the proteolytic cleavage of SREBP-1c and therefore suppresses the expression of its target genes in the liver (4). This process leads to the reduction of lipid synthesis and accumulation in the liver (4).

  1. Brown, M.S. and Goldstein, J.L. (1997) Cell 89, 331-40.
  2. Horton, J.D. et al. (2002) J Clin Invest 109, 1125-31.
  3. Browning, J.D. and Horton, J.D. (2004) J Clin Invest 114, 147-52.
  4. Li, Y. et al. (2011) Cell Metab 13, 376-88.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products